N-Q 1 a147224.txt SCHEDULE OF PORTFOLIO HOLDINGS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES Investment Company Act file number: 811-09329 ALLIANCEBERNSTEIN GLOBAL HEALTH CARE FUND, INC. (Exact name of registrant as specified in charter) 1345 Avenue of the Americas, New York, New York 10105 (Address of principal executive offices) (Zip code) Mark R. Manley Alliance Capital Management L.P. 1345 Avenue of the Americas New York, New York 10105 (Name and address of agent for service) Registrant's telephone number, including area code: (800) 221-5672 Date of fiscal year end: June 30, 2006 Date of reporting period: March 31, 2006 ITEM 1. SCHEDULE OF INVESTMENTS. 2 ALLIANCEBERNSTEIN GLOBAL HEALTH CARE FUND PORTFOLIO OF INVESTMENTS March 31, 2006 (unaudited) COMPANY SHARES U.S. $ VALUE ------------------------------------------ ------- ------------ COMMON STOCKS - 99.0% HEALTH CARE - 99.0% BIOTECHNOLOGY - 19.2% Abgenix, Inc. (a) 83,900 $ 1,887,750 Amgen, Inc. (a) 80,400 5,849,100 Amylin Pharmaceuticals, Inc. (a) 98,200 4,806,890 Genentech, Inc. (a) 98,780 8,347,898 Gilead Sciences, Inc. (a) 150,600 9,370,332 Luminex Corp. (a) 77,400 1,150,164 Medlmmune, Inc. (a) 61,800 2,260,644 Tanox, Inc. (a) 67,600 1,312,792 ------------ 34,985,570 ------------ DRUGS - 43.4% Allergan, Inc. 79,300 8,604,050 Cephalon, Inc. (a) 61,500 3,705,375 Eli Lilly & Co. 82,600 4,567,780 Forest Laboratories, Inc. (a) 88,200 3,936,366 Merck & Co., Inc. 137,700 4,851,171 Novartis AG 156,594 8,688,796 Ranbaxy Laboratories, Ltd. (GDR) 381,064 3,749,670 Roche Holding AG 62,995 9,361,903 Sanofi-Aventis 84,224 7,986,792 Shionogi & Co., Ltd. 295,000 4,838,171 Takeda Pharmaceutical Co., Ltd. 75,100 4,272,044 Teva Pharmaceutical Industries, Ltd. (ADR) 200,080 8,239,294 Wyeth 129,040 6,261,021 ------------ 79,062,433 ------------ MEDICAL PRODUCTS - 18.3% Alcon, Inc. 75,700 7,892,482 Bausch & Lomb, Inc. 35,000 2,229,500 Johnson & Johnson 67,500 3,997,350 Nobel Biocare Holding AG 36,035 8,029,297 St. Jude Medical, Inc. (a) 178,000 7,298,000 Zimmer Holdings, Inc. (a) 58,100 3,927,560 ------------ 33,374,189 ------------ MEDICAL SERVICES - 18.1% Caremark Rx, Inc. (a) 145,900 7,175,362 Medco Health Solutions, Inc. (a) 42,600 2,437,572 UnitedHealth Group, Inc. 151,800 8,479,548 WellPoint, Inc. (a) 192,000 14,866,560 ------------ 32,959,042 ------------ Total Common Stocks (cost $112,733,605) 180,381,234 ------------ PRINCIPAL AMOUNT COMPANY (000) U.S. $ VALUE ------------------------------------------ --------- ------------ SHORT-TERM INVESTMENT - 1.6% TIME DEPOSIT - 1.6% ING Bank 4.86%, 4/03/06 (cost $2,900,000) $2,900 $ 2,900,000 ------------ TOTAL INVESTMENTS - 100.6% (cost $115,633,605) 183,281,234 Other assets less liabilities - (0.6%) (1,174,152) ------------ NET ASSETS - 100% $182,107,082 ============ (a) Non-income producing security. Glossary of Terms: ADR - American Depositary Receipt GDR - Global Depositary Receipt COUNTRY BREAKDOWN* 64.0% United States 18.5% Switzerland 5.0% Israel 4.5% Japan 4.4% France 2.0% India 1.6% Short-Term ----- 100.0% Total Investments ===== * All data are as of March 31, 2006. The Fund's country breakdown is expressed as a percentage of total investments and may vary over time. Please note: The industry classifications presented herein are based on the industry categorization methodology of the Adviser. ITEM 2. CONTROLS AND PROCEDURES. (a) The registrant's principal executive officer and principal financial officer have concluded that the registrant's disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940, as amended) are effective at the reasonable assurance level based on their evaluation of these controls and procedures as of a date within 90 days of the filing date of this document. (b) There were no changes in the registrant's internal controls over financial reporting that occurred during the second fiscal quarter of the period that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting. ITEM 3. EXHIBITS. The following exhibits are attached to this Form N-Q: EXHIBIT NO. DESCRIPTION OF EXHIBIT ----------- ---------------------- 3 (a) (1) Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 3 (a) (2) Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 3 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. (Registrant AllianceBernstein Global Health Care Fund, Inc. By: /s/ Marc O. Mayer --------------------------------- Marc O. Mayer President Date: May 25, 2006 Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. By: /s/ Marc O. Mayer --------------------------------- Marc O. Mayer President Date: May 25, 2006 By: /s/ Mark D. Gersten --------------------------------- Mark D. Gersten Treasurer and Chief Financial Officer Date: May 25, 2006 4